Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy
Information source: Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Head and Neck Cancer
Intervention: capecitabine (Drug); Surgery, chemotherapy and/or radiotherapy (Procedure)
Phase: Phase 2
Status: Completed
Sponsored by: Barbara Ann Karmanos Cancer Institute Official(s) and/or principal investigator(s): George H. Yoo, MD, Study Chair, Affiliation: Barbara Ann Karmanos Cancer Institute
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving capecitabine after surgery, radiation therapy, and/or chemotherapy may kill any
remaining tumor cells.
PURPOSE: This phase II trial is studying how well capecitabine works in treating patients
who have undergone previous surgery, radiation therapy, and/or chemotherapy for head and
neck cancer.
Clinical Details
Official title: A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda®) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma (HNSCC) After Surgery, Radiation and/or Chemotherapy
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Feasibility of Treatment as Assessed.
Secondary outcome: Time to RecurrenceLocal-regional Control Rate Occurrence Survival Rate Incidence of Second Primary Tumor Occurrence
Detailed description:
OBJECTIVES:
Primary
- Determine the feasibility of adjuvant low-dose capecitabine in patients with squamous
cell carcinoma of the head and neck who have undergone prior curative surgery,
radiotherapy, and/or chemotherapy.
Secondary
- Determine the time to recurrence, local-regional control, and survival rate in patients
treated with this drug.
- Determine the incidence of second primary tumors in patients treated with this drug.
OUTLINE: This is an open-label study.
Patients receive oral capecitabine once daily for 1 year in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 1 year and
then every 6 months for 1 year.
PROJECTED ACCRUAL: A total of 41 patients will be accrued for this study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS:
- Histologically confirmed squamous cell carcinoma of the head and neck, including 1 of
the following primary tumor sites:
- Oral cavity
- Oropharynx
- Nasopharynx
- Hypopharynx
- Larynx
- Unknown primary
- Any disease stage allowed
- No evidence of active disease
- Must have undergone curative surgical resection, radiotherapy, and/or chemotherapy at
least 1 month, but no more than 4 years ago
PATIENT CHARACTERISTICS:
Performance status
- Karnofsky 70-100%
Life expectancy
- More than 3 months
Hematopoietic
- White blood count (WBC) ≥ 3,000/mm^3
- Granulocyte count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ 1. 5 times upper limit of normal (ULN)
- Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤ 2. 5 times ULN
- Alkaline phosphatase ≤ 2. 5 times ULN
- Hepatitis B and/or C negative
Renal
- Creatinine clearance > 50 mL/min
Cardiovascular
- No myocardial infarction within the past 12 months
- No uncontrolled congestive heart failure
- No unstable or uncontrolled angina
Gastrointestinal
- No lack of physical integrity of the upper gastrointestinal tract
- Must be able to swallow tablet
- No malabsorption syndrome
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer
for which the patient is currently in complete remission
- No history of uncontrolled seizures, central nervous system (CNS) disorders, or
psychiatric disability that would preclude study compliance or giving informed
consent
- No ongoing postoperative fistula
- No prior unanticipated severe reaction to fluoropyrimidine therapy or known
sensitivity to fluorouracil
- No other serious uncontrolled medical or surgical condition that would preclude study
participation
PRIOR CONCURRENT THERAPY:
Chemotherapy
- See Disease Characteristics
- Prior oral fluoropyrimidine therapy allowed provided it was given in the adjuvant
setting and completed ≥ 12 months ago
Radiotherapy
- See Disease Characteristics
Surgery
- See Disease Characteristics
- More than 4 weeks since prior major surgery and recovered
- No prior organ allografts
Other
- More than 4 weeks since prior participation in any investigational drug study
Locations and Contacts
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201-1379, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: December 2003
Last updated: January 15, 2015
|